SecBot SecBot
8-K ·Filed Feb 26, 2026

CCCC

C4 Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001628280-26-011971
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant revenue growth, improved cost structure, strong cash runway to 2028, and advancement of key clinical programs suggest C4T is executing well on its strategy. Traders should monitor upcoming clinical data readouts in mid-2026 and the initiation of the Phase 1b combination trial with elranatamab in Q2 2026 as potential catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.78
T+0 close · Feb 26, 2026 · via day close
Latest settled
+26.62%
T+60 · $3.52
Vs SPY
+18.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $2.78entry
  2. T+1 · 9mo ago −2.88%α −2.43% · $2.70
  3. T+5 · 9mo ago +8.99%α +10.12% · $3.03
  4. T+20 · 8mo ago −5.76%α +0.65% · $2.62
  5. T+60 · 6mo ago +26.62%α +18.87% · $3.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics reported financial results for Q4 and full year 2025, highlighted by a 112% YoY increase in quarterly revenue to $11.0 million driven by its collaboration with Merck, reduced R&D and G&A expenses, and a strengthened cash position of $297.1 million following a $125 million equity raise. The company advanced its lead candidate cemsidomide into a Phase 2 trial for multiple myeloma and earned a $2 million milestone from Biogen.

Key Financial Metrics

Revenue
$11.0M
+111.5% YoY
EPS
$-0.18

Key Facts

  • Revenue increased 112% YoY in Q4 2025 to $11.0 million, driven by prioritization of a KRAS project under the Merck collaboration
  • Full-year 2025 revenue was $35.9 million, up slightly from $35.6 million in 2024
  • R&D expenses decreased to $25.0 million in Q4 2025 from $32.5 million in Q4 2024 due to completion of the CFT1946 Phase 1 trial
  • G&A expenses decreased to $9.2 million in Q4 2025 from $10.4 million in Q4 2024 due to lower stock-based compensation
  • Net loss narrowed to $20.5 million in Q4 2025 from $34.6 million in Q4 2024; full-year net loss was $105.0 million vs $105.3 million in 2024
  • Cash, cash equivalents, and marketable securities totaled $297.1 million as of December 31, 2025, up from $199.8 million as of September 30, 2025, providing runway to end of 2028
  • Company raised $125 million in gross proceeds through an underwritten offering in October 2025
  • Earned $2 million milestone payment from Biogen in January 2026 related to BIIB145, a BTK degrader
  • First patient dosed in Phase 2 MOMENTUM trial for cemsidomide in multiple myeloma in February 2026
  • Phase 1b trial of cemsidomide in combination with elranatamab expected to initiate in Q2 2026

Financial Impact

Revenue increased by $5.8 million YoY in Q4 2025; cash position increased by $97.3 million from September 30, 2025 to $297.1 million as of December 31, 2025

revenuer&d expenseg&a expensenet losscash position

Risk Factors

  • Biotech stock with no approved products and significant clinical development risk
  • Future dilution risk from potential exercise of warrants issued in the October 2025 offering
  • Dependence on collaboration partners like Merck and Biogen for milestone payments and funding

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-011971
Document: cccc-20260226.htm0001628280-26-011971
Document: 0001628280-26-011971-index-headers.html0001628280-26-011971
Document: 0001628280-26-011971-index.html0001628280-26-011971
Document: 0001628280-26-011971.txt0001628280-26-011971

Track record

19 reports on CCCC

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026